Abstract
Background
The tuberculin skin test (TST) is a long-established screening method for tuberculosis. However, the Mantoux technique is often difficult to reliably perform, which affects testing results and safety, which causes local skin pain and pruritus.
Methods
In this study, dissolving microneedle-array patches (MNP) were used to deliver purified protein derivative (PPD) tuberculin into the skin. The skin reaction was compared between MNP delivery and conventional injection.
Results
The MNP penetrated the skin easily with a thumb press, and the microneedle dissolved into the skin completely after 1 h. The storage life of MNP loaded with PPD (MNP-PPD) was 7 weeks at atmospheric pressure and room temperature. Only 1/50 dosage of PPD (approximately 0.04 IU) was needed in MNP compared with conventional injection (2 IU) in terms of skin reactivity to TST. When TST was tested in volunteers, the redness and induration of the skin were 19.7 ± 5.6 mm in TB patients, 12.6 ± 4.4 mm in LTBI (latent TB infection) patients, and 5.8 ± 2.7 mm in BCG vaccination healthy volunteers and lasted approximately 26 ± 5.4 days. When applied with MNP-PPD, the redness and induration on the skin decreased significantly to 3.1 ± 0.7 mm in TB patients and 2.0 ± 0.5 mm in LTBI, and the duration time was only 8.5 ± 1.5 days. Moreover, despite the relatively mild skin reactivity in BCG vaccination healthy volunteers with conventional injection, there was no skin reactivity in BCG vaccination healthy volunteers with MNP-PPD.
Conclusion
In addition to being minimally invasive, needle-free, and painless, no adverse effects were attributed to the new diagnostic method, which may be of value for the safe and effective clinical administration of TB screening. When applied with MNP-PPD, an area of redness and induration greater than 2.5 mm can identify a TB-positive patient.
Similar content being viewed by others
Abbreviations
- TST:
-
Tuberculin skin test
- TB:
-
Tuberculosis
- MNP:
-
Microneedle-array patch
- PPD:
-
Purified protein derivative tuberculin
- LTBI:
-
Latent TB infection
- BCG:
-
Bacillus Calmette-Guerin
References
World Health Organization. Global tuberculosis report. 2016.
WHO fact sheet on tuberculosis (TB). Updated October 2017.
Konstantinos A. Testing for tuberculosis. Aust Prescr. 2010;33(1):12–8.
Gwee A, Pantazidou A, Ritz N, Tebruegge M, Connell TG, Cain T, et al. To X-ray or not to X-ray? Screening asymptomatic children for pulmonary TB: a retrospective audit. Arch Dis Child. 2013;98:401–4.
Lopez T, Moreno M, Salvador F, Zacarias A, Carvalho R, Tomas E, et al. Tuberculosis diagnosed in a rural setting in Angola. Accuracy of follow-up sputum smears to predict outcome. Pathog Glob Health. 2013;107:5–10.
Kidenya BR, Kabangila R, Peck RN, Mshana SE, Webster LE, Koenig SP, et al. Early and efficient detection of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. PLoS One. 2013;8:e57527.
Ajantha GS, Shetty PC, Kulkarni RD, Biradar U. PCR as a diagnostic tool for extra-pulmonary tuberculosis. J Clin Diagn Res. 2013;7:1012–5.
Moure R, Martin R, Alcaide F. Effectiveness of an integrated real-time PCR method for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples in an area of low tuberculosis prevalence. J Clin Microbiol. 2012;50:513–5.
Mehta PK, Raj A, Singh N, Khuller GK. Diagnosis of extrapulmonary tuberculosis by PCR. FEMS Immunol Med Microbiol. 2012;66:20–36.
Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.
Dheda K, Smit RZ, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in highburden vs. low-burden settings. Curr Opin Pulm Med. 2009;15:188–200.
Raja A, Ranganathan UD, Bethunaickan R. Improved diagnosis of pulmonary tuberculosis by detection of antibodies against multiple Mycobacterium tuberculosis antigens. Diagn Microbiol Infect Dis. 2008;60:361–8.
Taubman D, Titler N, Edelstein H, Elias M, Saliba W. Providing detailed information about latent tuberculosis and compliance with the PPD test among healthcare workers in Israel: a randomized controlled study. J Epidemiol Glob Health. 2013;3:253–60.
Jam S, Sabzvari D, SeyedAlinaghi S, Fattahi F, Jabbari H, Mohraz M. Frequency of Mycobacterium tuberculosis infection among Iranian patients with HIV/AIDS by PPD test. Acta Med Iran. 2010;48:67–71.
Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547–68.
Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187–207.
Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64:11–29.
Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56:581–7.
Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008;24(September (7)):585–94.
Kaushik S, Hord AH, Denson DD, McAllister DV, Smitra S, Allen MG, et al. Lack of pain associated with microfabricated microneedles. Anesth Analg. 2001;92:502–4.
Chen F, Yan Q, Yu Y, Wu MX. BCG vaccine powder-laden and dissolvable microneedle arrays for lesion free vaccination. J Control Release. 2017;255:36–44.
Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16:915–20.
Yan Q, Liu H, Cheng Z, Xue Y, Cheng Z, Dai X, et al. Immunotherapeutic effect of BCG-polysaccharide nucleic acid powder on Mycobacterium tuberculosis-infected mice using microneedle patches. Drug Deliv. 2017;24(1):1648–53.
Jin J, Reese V, Coler R, Carter D, Rolandi M. Chitin microneedles for an easy-to-use tuberculosis skin test. Adv Healthc Mater. 2014;3(3):349–53.
Yan Q, Cheng Z, Liu H, Shan W, Cheng Z, Dai X, et al. Enhancement of Ag85B DNA vaccine immunogenicity against tuberculosis by dissolving microneedles in mice. Vaccine. 2018;36(30):4471–6.
Wu D, Quan YS, Kamiyama F, Kusamori K, Katsumi H, Sakane T, et al. Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedle array fabricated from sodium hyaluronate in rats. Biol Pharm Bull. 2015;38(3):365–73.
Pan W, Matizirofa L, Workman L, Hawkridge T, Hanekom W, Mahomed H, et al. Comparison of mantoux and tine tuberculin skin tests in BCG-vaccinated children investigated for tuberculosis. PLoS One. 2009;4:e8085.
Lee HJ, Choi HJ, Kim DR, Lee H, Jin JE, Kim YR, et al. Safety and efficacy of tuberculin skin testing with microneedle MicronJet600™ in healthy adults. Int J Tuberc Lung Dis. 2016;20(4):500–4.
Cao Y, Kakar P, Hossen MN, Wu MX, Chen X. Sustained epidermal powder drug delivery via skin microchannels. J Control Release. 2017;249:94–102.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–51.
Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221–47.
Eilers PH, Borgdorff MW. Modeling and correction of digit preference in tuberculin surveys. Int J Tuberc Lung Dis. 2004;8:232–9.
Bekmurzayeva A, Sypabekova M, Kanayeva D. Tuberculosis diagnosis using immunodominant, secreted antigens of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2013;93:381–8.
Guinn KM, Hickey MJ, Mathur SK, Zakel KL, Grotzke JE, Lewinsohn DM, et al. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol. 2004;51:359–70.
Li F, Xu M, Zhou L, Xiong Y, Xia L, Fan X, et al. Safety of recombinant fusion protein ESAT6-CFP10 as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, single-center phase I clinical trial. Clin Vaccine Immunol. 2016;23(9):767–73.
Research funding
This work was supported by National Key Research and Development Program of China (No. 2018YFC0809200), Guangdong Science and Technology Foundation (No. 2017A030313668, No. 2017B020210006), Shenzhen Science and Technology Foundation (No. CKCY20170720100145397, No. GJHS20170314161153714, No. JCYJ20170307104024209). The health and family planning commission of Wuhan municipality (WX17A09) and the Wuhan middle and young backbone talent program provided funding. The Natural Science Foundation of Hubei Province (ZRMS2019001095) also provided funding.
Author information
Authors and Affiliations
Contributions
All of the authors have accepted responsibility for the entire content of this submitted manuscript and approve the submission.
Corresponding author
Ethics declarations
All of the studies were reviewed and approved by the Ethics Committee of Hubei University.
Conflict of interests
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Wei Wang, Hou Ming Liu, and Jing Zhou are joint first authors
Rights and permissions
About this article
Cite this article
Wang, W., Liu, H.M., Zhou, J. et al. Skin test of tuberculin purified protein derivatives with a dissolving microneedle-array patch. Drug Deliv. and Transl. Res. 9, 795–801 (2019). https://doi.org/10.1007/s13346-019-00629-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13346-019-00629-y